T-cell alterations in hemophiliacs treated with commercial clotting factor concentrates.
Various immunological parameters were determined in 46 patients with severe hemophilia A and in 9 patients with severe hemophilia B. All patients were treated over many years with commercial factor VIII or IX concentrates. Patients with severe classic hemophilia had a significantly reduced relative and absolute number of T-helper cells and a significantly increased relative and absolute number of T-suppressor cells. About half of these patients had an inverse T-helper/suppressor cell ratio. Patients with moderate hemophilia A and severe hemophilia B did not show these abnormalities. Hemophiliacs with an inverse ratio had a significantly higher concentration of serum total protein, IgG and IgM. No relationship between the amount of factor VIII concentrate administered, the HLA-type of the patient, the presence or absence of CMV-antibodies, hepatitis markers, thrombocytopenia and abnormal liver function tests to the T-cell abnormalities could be established. Lymphadenopathy was frequently associated with an inverse ratio. Indirect evidence suggests that the alterations of the immune system began in 1979/80.
D000163:Acquired Immunodeficiency Syndrome / Q000209:etiology; D000293:Adolescent; D000328:Adult; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology; D005164:Factor IX / Q000008:administration & dosage*; D005169:Factor VIII / Q000008:administration & dosage*; D006467:Hemophilia A / Q000150:complications / Q000276:immunology* / Q000628:therapy; D002836:Hemophilia B / Q000276:immunology* / Q000628:therapy; D006509:Hepatitis B / Q000209:etiology / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer; D050378:T-Lymphocytes, Regulatory; D013921:Thrombocytopenia / Q000150:complications
D007074:Immunoglobulin G; D005169:Factor VIII; D005164:Factor IX